T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis.

Abatacept improves digestive involvement, prevents lung fibrosis, and attenuates PH. These findings suggest that abatacept might be an appealing therapeutic approach beyond skin fibrosis for organ involvement in SSc.